IE
MNPR icon

Israel Englander’s Monopar Therapeutics MNPR Stock Holding History

Israel Englander’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.66M Sell
50,311
-2,640
-5% -$163K ﹤0.01% 3055
2026
Q1 		$2.9M Sell
52,951
-23,723
-31% -$1.43M ﹤0.01% 3501
2025
Q4 		$5.01M Buy
76,674
+69,340
+945% +$5.67M ﹤0.01% 3011
2025
Q3 		$599K Sell
7,334
-7,455
-50% -$333K ﹤0.01% 4962
2025
Q2 		$529K Sell
14,789
-45,578
-76% -$1.66M ﹤0.01% 4873
2025
Q1 		$2.2M Buy
+60,367
New +$2.18M ﹤0.01% 3688
2024
Q3 		– Sell
-38,860
Closed -$145K – 6331
2024
Q2 		$145K Buy
38,860
+384
+1% +$1.35K ﹤0.01% 5237
2024
Q1 		$131K Buy
38,476
+32,608
+556% +$97.2K ﹤0.01% 5510
2023
Q4 		$9.98K Buy
5,868
+2,066
+54% +$4.18K ﹤0.01% 5741
2023
Q3 		$10.8K Sell
3,802
-2,750
-42% -$9.61K ﹤0.01% 5753
2023
Q2 		$28K Buy
+6,552
New +$33.5K ﹤0.01% 5585
2020
Q2 		– Sell
-2,301
Closed -$85K – 4436
2020
Q1 		$85K Buy
+2,301
New +$144K ﹤0.01% 3580

Other funds holding MNPR

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Israel Englander's MNPR Position: Q2 2026 in Review

Israel Englander reduced its Monopar Therapeutics (MNPR) stake by 5% in Q2 2026, selling an estimated $163K and leaving 50,311 shares worth $4.66M. The position accounts for ﹤0.01% of the portfolio, ranked #3055.

Israel Englander first reported a position in MNPR in Q1 2020 and has held it in 12 quarters since. The position peaked at $5.01M in Q4 2025. 95 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

  • Israel Englander held 50,311 shares of Monopar Therapeutics worth $4.66M as of Q2 2026.
  • Israel Englander sold 2,640 Monopar Therapeutics shares in Q2 2026, an estimated $163K.
  • Monopar Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #3055 holding.
  • Israel Englander first reported a position in Monopar Therapeutics in Q1 2020 and has held it in 12 quarters since.
  • Israel Englander's Monopar Therapeutics position peaked at $5.01M in Q4 2025.
  • 95 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.